The Landmark Series: Neuroendocrine Tumor Liver Metastases

Abstract

Background

Neuroendocrine tumors are becoming increasingly prevalent, with many patients presenting with or developing metastatic disease to the liver.

Methods

In this landmark series paper, we highlight the critical studies that have defined the surgical management of neuroendocrine tumor liver metastases, as well as several randomized control trials which have investigated strategies for systemic control of metastatic disease.

Results

Liver-directed surgical approaches and locally ablative procedures are recommended for patients with limited, resectable, and in some cases, nonresectable tumor burden. Angiographic liver-directed techniques, such as transarterial embolization, chemoembolization, and radioembolization, offer another approach for management in patients with liver-predominant disease. Peptide receptor radionuclide therapy is a promising therapy for patients with hepatic and/or extrahepatic metastases. Various systemic medical therapies are also available as adjunct or definitive therapy for patients with metastatic disease.

Conclusions

This article reviews current data regarding management of neuroendocrine liver metastases and highlights areas for future study.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342. https://doi.org/10.1001/jamaoncol.2017.0589.

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–959. https://doi.org/10.1002/cncr.11105.

    Article  PubMed  Google Scholar 

  3. 3.

    Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190(4):432–445. https://doi.org/10.1016/s1072-7515(00)00222-2.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072. https://doi.org/10.1200/jco.2007.15.4377.

    Article  PubMed  Google Scholar 

  5. 5.

    Niederle B, Pape U-F, Costa F, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103(2):125–138. https://doi.org/10.1159/000443170.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Pavel M, Baudin E, Couvelard A, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–176. https://doi.org/10.1159/000335597.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16(3):885–894. https://doi.org/10.1677/erc-09-0042.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(17):2372-2377. https://doi.org/10.1200/jco.2010.33.0688.

    Article  Google Scholar 

  9. 9.

    Kim JY, Hong S-M, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 2017;29:11–16. https://doi.org/10.1016/j.anndiagpath.2017.04.005.

    Article  PubMed  Google Scholar 

  10. 10.

    Foster JH, Berman MM. Solid liver tumors. Major Probl Clin Surg. 1977;22:1–342.

    CAS  PubMed  Google Scholar 

  11. 11.

    Foster J, Lundy J. Liver Metastases. In: Current Problems in Surgery. 1981; 18:157–202.

  12. 12.

    McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108(6):1091–1096.

    CAS  PubMed  Google Scholar 

  13. 13.

    Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169(1):36–42; discussion 42-43. https://doi.org/10.1016/s0002-9610(99)80107-x.

  14. 14.

    Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37. https://doi.org/10.1016/s1072-7515(03)00230-8.

    Article  PubMed  Google Scholar 

  15. 15.

    Chambers AJ, Pasieka JL, Dixon E, Rorstad O. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery. 2008;144(4):645–651; discussion 651-653. https://doi.org/10.1016/j.surg.2008.06.008.

  16. 16.

    Graff-Baker AN, Sauer DA, Pommier SJ, Pommier RF. Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patients. Surgery. 2014;156(6):1369–1376; discussion 1376-1377. https://doi.org/10.1016/j.surg.2014.08.009.

  17. 17.

    Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163(1):218–225. https://doi.org/10.1016/j.surg.2017.05.030.

    Article  PubMed  Google Scholar 

  18. 18.

    Maxwell JE, Sherman SK, O’Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016;159(1):320–333. https://doi.org/10.1016/j.surg.2015.05.040.

    Article  PubMed  Google Scholar 

  19. 19.

    Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17(12):3129–3136. https://doi.org/10.1245/s10434-010-1154-5.

    Article  PubMed  Google Scholar 

  20. 20.

    Boudreaux JP, Wang Y-Z, Diebold AE, et al. A single institution’s experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroendocrine tumors. J Am Coll Surg. 2014;218(4):837–844. https://doi.org/10.1016/j.jamcollsurg.2013.12.035.

    Article  PubMed  Google Scholar 

  21. 21.

    Scott AT, Breheny PJ, Keck KJ, et al. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. 2019;165(1):166–175. https://doi.org/10.1016/j.surg.2018.04.070.

    Article  PubMed  Google Scholar 

  22. 22.

    Saxena A, Chua TC, Perera M, Chu F, Morris DL. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol. 2012;21(3):e131–e141. https://doi.org/10.1016/j.suronc.2012.05.001.

    Article  PubMed  Google Scholar 

  23. 23.

    Howe JR, Cardona K, Fraker DL, et al. The surgical management of small bowel neuroendocrine tumors: Consensus guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46(6):715–731. https://doi.org/10.1097/mpa.0000000000000846.

    Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society Consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(1):1–33. https://doi.org/10.1097/mpa.0000000000001454.

    Article  PubMed  Google Scholar 

  25. 25.

    Elias D, Lefevre JH, Duvillard P, et al. Hepatic metastases from neuroendocrine tumors with a “thin slice” pathological examination: they are many more than you think. Ann Surg. 2010;251(2):307–310. https://doi.org/10.1097/sla.0b013e3181bdf8cf.

    Article  PubMed  Google Scholar 

  26. 26.

    Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review. Surgery. 2017;162(3):525–536. https://doi.org/10.1016/j.surg.2017.05.006.

    Article  PubMed  Google Scholar 

  27. 27.

    Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol. 2007;47(4):460–466. https://doi.org/10.1016/j.jhep.2007.07.004.

    Article  PubMed  Google Scholar 

  28. 28.

    Mazzaferro V, Sposito C, Coppa J, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant. 2016;16(10):2892–2902. https://doi.org/10.1111/ajt.13831.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Gedaly R, Daily MF, Davenport D, et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg Chic Ill 1960. 2011;146(8):953–958. https://doi.org/10.1001/archsurg.2011.186.

  30. 30.

    Fan ST, Le Treut YP, Mazzaferro V, et al. Liver transplantation for neuroendocrine tumour liver metastases. HPB. 2015;17(1):23–28. https://doi.org/10.1111/hpb.12308.

    Article  PubMed  Google Scholar 

  31. 31.

    Norlén O, Daskalakis K, Öberg K, Åkerström G, Stålberg P, Hellman P. Indication for liver transplantation in young patients with small intestinal NETs is rare? World J Surg. 2014;38(3):742–747. https://doi.org/10.1007/s00268-013-2331-z.

    Article  PubMed  Google Scholar 

  32. 32.

    Gamblin TC, Christians K, Pappas SG. Radiofrequency ablation of neuroendocrine hepatic metastasis. Surg Oncol Clin N Am. 2011;20(2):273-279, vii-viii. https://doi.org/10.1016/j.soc.2010.11.002.

  33. 33.

    Mayo SC, de Jong MC, Bloomston M, et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol. 2011;18(13):3657–3665. https://doi.org/10.1245/s10434-011-1832-y.

    Article  PubMed  Google Scholar 

  34. 34.

    Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142(1):10–19. https://doi.org/10.1016/j.surg.2007.01.036.

    Article  PubMed  Google Scholar 

  35. 35.

    Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol. 2008;15(10):2757–2764. https://doi.org/10.1245/s10434-008-0043-7.

    Article  PubMed  Google Scholar 

  36. 36.

    Cannon R, Ellis S, Hayes D, Narayanan G, Martin RCG. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2013;107(5):544–549. https://doi.org/10.1002/jso.23280.

    Article  PubMed  Google Scholar 

  37. 37.

    Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13(4):572–581. https://doi.org/10.1245/aso.2006.03.071.

    Article  PubMed  Google Scholar 

  38. 38.

    Kennedy AS. Hepatic-directed therapies in patients with neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30(1):193–207. https://doi.org/10.1016/j.hoc.2015.09.010.

    Article  PubMed  Google Scholar 

  39. 39.

    Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104(8):1590–1602. https://doi.org/10.1002/cncr.21389.

    Article  PubMed  Google Scholar 

  40. 40.

    de Baere T, Deschamps F, Tselikas L, et al. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol. 2015;172(4):R151–R166. https://doi.org/10.1530/eje-14-0630.

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol Northwood Lond Engl. 2011;28 Suppl 1:S286–S290. https://doi.org/10.1007/s12032-010-9750-6.

    Article  Google Scholar 

  42. 42.

    Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control J Moffitt Cancer Cent. 2006;13(1):72–78. https://doi.org/10.1177/107327480601300110.

    Article  Google Scholar 

  43. 43.

    Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol. 2007;188(5):1201–1207. https://doi.org/10.2214/ajr.06.0933.

    Article  PubMed  Google Scholar 

  44. 44.

    Bhagat N, Reyes DK, Lin M, et al. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol. 2013;36(2):449–459. https://doi.org/10.1007/s00270-012-0424-y.

    Article  PubMed  Google Scholar 

  45. 45.

    Cao CQ, Yan TD, Bester L, Liauw W, Morris DL. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg. 2010;97(4):537–543. https://doi.org/10.1002/bjs.6931.

    CAS  Article  PubMed  Google Scholar 

  46. 46.

    Gebhard TA, Suhocki P, Engstrom BI, et al. Metastatic neuroendocrine tumors to the liver: treatment with bland embolization versus radioembolization. J Vasc Interv Radiol. 2013;24(4):S13. https://doi.org/10.1016/j.jvir.2013.01.034.

    Article  Google Scholar 

  47. 47.

    Chen JX, Wileyto EP, Soulen MC. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials. 2018;19(1):390. https://doi.org/10.1186/s13063-018-2782-5.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  48. 48.

    Rinke A, Müller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(28):4656–4663. https://doi.org/10.1200/jco.2009.22.8510.

    CAS  Article  Google Scholar 

  49. 49.

    Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–233. https://doi.org/10.1056/nejmoa1316158.

    CAS  Article  PubMed  Google Scholar 

  50. 50.

    Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet Lond Engl. 2016;387(10022):968–977. https://doi.org/10.1016/s0140-6736(15)00817-x.

    CAS  Article  Google Scholar 

  51. 51.

    Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513. https://doi.org/10.1056/nejmoa1003825.

    CAS  Article  PubMed  Google Scholar 

  52. 52.

    Kunz PL, Catalano PJ, Nimeiri H, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol. 2018;36(15_suppl):4004–4004. https://doi.org/10.1200/jco.2018.36.15_suppl.4004.

  53. 53.

    Cives M, Ghayouri M, Morse B, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2016;23(9):759–767. https://doi.org/10.1530/erc-16-0147.

    CAS  Article  PubMed  Google Scholar 

  54. 54.

    Krenning EP, Kooij PP, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;733:496-506. https://doi.org/10.1111/j.1749-6632.1994.tb17300.x.

  55. 55.

    Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(13):2124–2130. https://doi.org/10.1200/jco.2007.15.2553.

    CAS  Article  Google Scholar 

  56. 56.

    Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–135. https://doi.org/10.1056/nejmoa1607427.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to James R. Howe MD.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gangi, A., Howe, J.R. The Landmark Series: Neuroendocrine Tumor Liver Metastases. Ann Surg Oncol 27, 3270–3280 (2020). https://doi.org/10.1245/s10434-020-08787-x

Download citation

Keywords

  • Neuroendocrine
  • Liver metastases
  • Liver debulking
  • PRRT